Sleep Disturbance Clinical Trial
Official title:
Medical Management of Sleep Disturbance During Opioid Tapering
Verified date | July 2022 |
Source | Johns Hopkins University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will evaluate whether a dual orexin-receptor antagonist approved by the FDA for sleep disturbance, suvorexant (SUVO; Belsomra), will increase total sleep time in patients with opioid use disorder (OUD) undergoing supervised withdrawal. This study is designed as a dose-finding study of SUVO compared to placebo. Briefly, OUD patients seeking supervised withdrawal will be admitted into a clinical research unit and stabilized onto buprenorphine for three days before being randomly assigned to study condition. All participants will then undergo a routine four-day buprenorphine taper, followed by a four-day post-taper phase. Participants will be randomized to receive either placebo, Low Dose SUVO, or High Dose SUVO and the investigators hypothesize that one or both doses of SUVO will improve total sleep time relative to placebo. Patients will attend a single follow-up session, 5-10 days following discharge.
Status | Completed |
Enrollment | 90 |
Est. completion date | June 10, 2021 |
Est. primary completion date | June 10, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Aged 18 years old and above - Meets Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria for OUD with evidence of physical dependence on opioids, and seeking treatment to stop using illicit opioids. - Provides a urine sample that tests positive for opioids. - Willing to comply with the study protocol. - Have no clinically significant chronic medical or surgical disorders or conditions that are judged by the investigators to prevent participation. Exclusion Criteria: - Seeking or currently enrolled in methadone or buprenorphine maintenance treatment for OUD - Pregnant or breast feeding - Have evidence of physical dependence on alcohol or benzodiazepines that requires medical detoxification - Have a known allergy to the study medications - Past 30-day prescribed use of suvorexant or benzodiazepines for the indication of insomnia - Current use of a Selective Serotonin Reuptake Inhibitor (SSRI) or Monoamine oxidase (MAO) inhibitor for depression or insomnia, or other medications that are contraindicated with suvorexant - Current narcolepsy, restless leg syndrome or sleep paralysis - High risk for current sleep apnea - Current major depressive disorder - Past year suicidal behavior - Severe hepatic or renal impairment - Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) >3x ULN - Total bilirubin >2x Upper Limit of Normal (ULN) - Creatinine >1.5x ULN - Have circumstances that would interfere with study participation (e.g., impending jail) |
Country | Name | City | State |
---|---|---|---|
United States | Johns Hopkins Bayview Medical Center | Baltimore | Maryland |
Lead Sponsor | Collaborator |
---|---|
Johns Hopkins University | National Institute on Drug Abuse (NIDA) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Abuse Liability as Assessed by Visual Analogue Scale | Area-under-the-curve of self-reported feelings of drug "High" on the morning after study drug administration, measured each morning on a 0-100 point visual analogue scale of the question "Last night, did you feel HIGH?". A score of "0" indicates no abuse liability and a score of 100 indicates extreme abuse liability. This will be assessed over four nights during an opioid taper. | 4 nights | |
Primary | Total Sleep Time During Buprenorphine Taper | Area-under-the-curve scores of total number of minutes slept per night as measured by a 3-lead wireless electroencephalography and wrist worn actigraphy. | Four nights during a buprenorphine taper | |
Primary | Total Sleep Time During Post-taper | Area-under-the-curve scores of total number of minutes slept per night as measured by a 3-lead wireless electroencephalography and wrist worn actigraphy. | Four nights following buprenorphine discontinuation | |
Primary | Subjective Opiate Withdrawal Scale During Buprenorphine Taper | Area-under-the-curve of peak daily scores on the Subjective Opiate Withdrawal Scale (SOWS) (a 16-item self-reported scale that measures individual opioid withdrawal symptoms using a 0-4 Likert scale; total range of SOWS is 0-64; lower scores indicate mild opioid withdrawal relative to higher scores which indicate more severe opioid withdrawal). | Three days during a buprenorphine taper | |
Primary | Subjective Opiate Withdrawal Scale During Post-taper | Area-under-the-curve of peak daily scores on the Subjective Opiate Withdrawal Scale (SOWS) (a 16-item self-reported scale that measures individual opioid withdrawal symptoms using a 0-4 Likert scale; total range of SOWS is 0-64; lower scores indicate mild opioid withdrawal relative to higher scores which indicate more severe opioid withdrawal). | Three days following buprenorphine discontinuation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04959214 -
The Effect Of Progressıve Relaxatıon Exercıses
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Completed |
NCT05555186 -
The Effects of Bright Light Therapy on Adolescent's Sleep Quality and Well-being
|
N/A | |
Completed |
NCT05093465 -
A Comparison of Two Behavioral Sleep Interventions Among College Students (ProjectTECH)
|
N/A | |
Completed |
NCT03673397 -
The Acute Effect of Aerobic Exercise on Sleep in Patients With Depression
|
N/A | |
Recruiting |
NCT04368416 -
Anxiety/Depression, Sleep and Alcohol in Elderly Anxiety/Depression, Sleep Disturbances and Alcohol Use Disorder in Elderly With Cognitive Complaints
|
||
Completed |
NCT04566822 -
Calm Sleep Coaching
|
N/A | |
Not yet recruiting |
NCT06406309 -
Settling Down for Sleep in ADHD: The Impact of Sensory and Arousal Systems on Sleep in ADHD
|
N/A | |
Recruiting |
NCT00860756 -
Sleep Disturbance in Deployed Soldiers
|
Phase 0 | |
Recruiting |
NCT05699837 -
Alpha Entrainment for Pain and Sleep (Extension)
|
N/A | |
Completed |
NCT06108115 -
Smartphone-Based Intervention for Sleep Disturbance in Individuals Recovering From Alcohol Use Disorder
|
N/A | |
Completed |
NCT05511818 -
Radicle Rest: A Study of Cannabinoids on Sleep and Health Outcomes
|
N/A | |
Completed |
NCT04560595 -
Remote Guided Caffeine Reduction
|
N/A | |
Not yet recruiting |
NCT06104280 -
Medications for Opioid Use Disorder Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment
|
N/A | |
Enrolling by invitation |
NCT04290650 -
Sleep Disturbances in Patients With Psychotic Symptoms (AkuSleep)
|
N/A | |
Recruiting |
NCT04207502 -
Integrating Systematic Data of Geriatric Medicine to Explore the Solution for Health Aging
|
||
Suspended |
NCT03908905 -
Sleep Disturbances and Chronic Widespread Pain
|
||
Completed |
NCT03269760 -
Multimodal Sleep Pathway for Shoulder Arthroplasty
|
Phase 1 | |
Completed |
NCT04990206 -
Improving Sleep Health in Adults With Overweight or Obesity
|
N/A | |
Completed |
NCT03112824 -
Functional Assessment of Ashwagandaha Root Extract During Weight Loss
|
N/A |